Novo Nordisk said a cyberattack exposed data from its Ozempic and Wegovy clinical trials.
The breach involved pseudonymous records that cannot be directly linked to individual patients. The company discovered the intrusion, isolated the affected systems, and is working with security consultants to assess the scope. No evidence yet suggests the data was copied or sold.
This matters because the trials underpin regulatory approvals and pricing for two of the most prescribed obesity treatments. Even stripped identifiers, the data could help competitors or researchers infer trial results, potentially influencing market dynamics and future research.
While the company downplays immediate risk to patients, the incident highlights the continuing vulnerability of pharma’s increasingly digital research pipelines.